{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:29:38Z","timestamp":1786512578554,"version":"build-2736575974"},"reference-count":26,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Due to their dependence on parenteral nutrition, patients with intestinal failure (IF) are at an increased risk of central line\u2010associated blood stream infections (CLABSIs). Ethanol lock therapies (ELTs) reduce the incidence of CLABSIs, but ELTs work locally in the line and have limited availability in the United States. Rifaximin is a non\u2010absorbed, enteral antibiotic used to manage small intestinal bacterial overgrowth (SIBO). Our primary objective was to evaluate the effectiveness of rifaximin to prevent CLABSIs in pediatric IF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of patients with IF managed at a single pediatric center between January 2010 and December 2022. Patients in the cohort had at least 1 CLABSI prior to initiation of rifaximin. Data were collected for 12 months pre\u2010 and post\u2010rifaximin initiation. CLABSI incidences were compared using Poisson regression with a log transformation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010three patients were included. The observed incidence of CLABSI for all patients in our sample, before and after rifaximin initiation, was 10.2 (8.2, 12.7) and 7.3 (5.8, 9.2) per 1000 central line days, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03. Subgroup analysis showed patients who received rifaximin without ELT had signification reduction in CLABSIs, 8.3 versus 3.0 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). There were no statistically significant differences in the proportion of gram\u2010positive or gram\u2010negative bacteria or yeast isolated before and after rifaximin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Children with IF who were treated with rifaximin experienced fewer CLABSI events, suggesting that rifaximin is a viable option for CLABSI prophylaxis in pediatric IF patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jpn3.70522","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:55:16Z","timestamp":1785495316000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of rifaximin in reducing central line\u2010associated bloodstream infections in pediatric intestinal failure"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6429-6453","authenticated-orcid":false,"given":"Emma","family":"Johnson","sequence":"first","affiliation":[{"name":"Department of Pharmacy American Family Children's Hospital Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Konicek","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Ann &amp; Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lamb","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Ann &amp; Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fishbein","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Ann &amp; Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Ann &amp; Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cohran","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Hepatology, and Nutrition, Ann &amp; Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"1","key":"e_1_2_7_2_1","first-page":"S98","article-title":"Intestinal failure among adults and children: similarities and differences","volume":"38","author":"Belza C","year":"2023","journal-title":"Nutr Clin Pract"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17150"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13147"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003036"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.1043"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2014.3291"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607110362758"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.2369"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piu079"},{"key":"e_1_2_7_11_1","unstructured":"American Society of Health\u2010System Pharmacists. Drug shortages [database] (ASHP 2026)."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549030-00009"},{"key":"e_1_2_7_13_1","volume-title":"Package Insert","author":"Rifaximin","year":"2023"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13928"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-014-0049-x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2014.106"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.12.008"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04826.x"},{"issue":"10","key":"e_1_2_7_19_1","first-page":"1314","article-title":"Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome","volume":"17","author":"Scarpellini E","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/children12030351"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3181effa3b"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000081992"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003506"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.2644"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.1989"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00363"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.761192"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70522","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpn3.70522","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:58:07Z","timestamp":1786510687000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpn3.70522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":26,"alternative-id":["10.1002\/jpn3.70522"],"URL":"https:\/\/doi.org\/10.1002\/jpn3.70522","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"jpn3.70522"}}